Peter J. Neumann, Sc.D., is Director of the Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine. Prior to joining Tufts, he was on the faculty of the Harvard School of Public Health for ten years. His research focuses on the use of cost-effectiveness analysis in health care decision making. He has conducted numerous economic evaluations of medical technologies, including evaluations of treatments for Alzheimer’s disease. He is the founder and director of the Cost-Effectiveness Registry (www.cearegistry.org), a comprehensive database of cost-effectiveness analyses in health care. Dr. Neumann has contributed to the literature on the use of willingness to pay and quality-adjusted life years (QALYs) in valuing health benefits. His other research has focused on the Food and Drug Administration’s regulation of health economic information, and the role of clinical and economic evidence in informing public and private sector health care decisions, including those made by the Medicare program. He is the author or co-author of over 150 papers in the medical literature, and the author of Using Cost-Effectiveness Analysis to Improve Health Care (Oxford University Press, 2005). He is a member of the editorial boards of Health Affairs and Value in Health. Dr. Neumann has served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and as a trustee of the Society for Medical Decision Making. He has also held several policy positions in Washington, including Special Assistant to the Administrator at the Health Care Financing Administration. He received his doctorate in health policy and management from the Harvard University.
Recent Posts by Peter J. Neumann
While compelling arguments exist for value frameworks to assume a societal perspective, in practice it is challenging for them to do so.
While CEAs of pharmaceutical interventions are vital, the disproportionate application of CEA to certain types of interventions can lead to less efficient use of health care dollars overall.
Cures Act, FDA Draft Guidance Suggest Flexibility On Communication Of Real-World Drug Impacts, Though Questions Remain
A key question pertains to the “real-world” impacts of prescription drugs, such as their potential to improve adherence, prevent hospitalizations, and reduce health costs.
February 2, 2017 | Drugs and Medical Innovation
Health technology assessment will likely play an integral role in health care’s paradigm shift from a system that rewards volume to one that rewards value. More controversial, however, is the role of budgetary criteria in determining value and in governing access to health care technologies.
A new discussion draft of the 21st Century Cures Act, the bipartisan initiative to accelerate development of new medical treatments, includes a section entitled “Facilitating Dissemination of Health Care Economic Information.”
Medicare is poised to revise its “coverage with evidence development” (CED) policy, which has important implications for beneficiaries’ access to new medical technology as well as manufacturers’ reimbursement for their products. For years, Medicare has employed CED, under which the program...
I had the good fortune to attend and participate in the Colorado Health Symposium, sponsored by the Colorado Health Foundation on July 28 in beautiful Keystone, Colorado. The symposium brought together 400 health professionals from Colorado, representing a variety of backgrounds, to discuss...